Patient-derived Organoids of Lung Cancer to Test Drug Response

The aim of the project is to use a combination of patient-derived organoid models: * To amplify tumour tissue to obtain enough material for genomic and histological analysis * to characterize the lung cancer sub-type * To predict treatment (non)response. The following points will be addressed: 1. First, the investigators plan to establish and characterize formation of organoids from biopsies of patients with lung cancer: in spheroids, in the 3D cellular model OncoCilAirTM (OncoTheis), and on the chick chorioallantoic membrane (CAM). Patient-derived organoids from tumoural tissue (PDO) will be characterized and compared to the original tumour. 2. Second, the investigators will test the chemoresponse (chemosensitivity and chemoresistance) of organoids to anti-cancer treatment.